Verrica Pharmaceuticals Settles Litigation, Dormer Labs Halts US Sales of Cantharidin Products

7/1/24 7:42:38 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $VRCA alert in real time by email

Verrica Pharmaceuticals Inc. ("Verrica") (NASDAQ:VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced the settlement of litigation with Dormer Laboratories, Inc. ("Dormer Labs"). As part of the settlement, Dormer Labs has discontinued the sale of all cantharidin-containing products into the United States, including Dormer brands Cantharone (Liquid) and Cantharone Plus.

Get the next $VRCA alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$VRCA

Date	Price Target	Rating	Analyst
11/6/2024		Buy → Neutral	H.C. Wainwright
11/5/2024		Outperform → Sector Perform	RBC Capital Mkts
7/25/2023	$10.00	Hold → Buy	Needham
3/22/2023	$10.00	Buy	Jefferies
2/13/2023	$4.00 → $11.00	Sector Perform → Outperform	RBC Capital Mkts
5/25/2022	$16.00 → $4.00	Outperform → Sector Perform	RBC Capital Mkts
3/10/2022	$20.00	Buy	Brookline Capital
3/3/2022	$20.00 → $18.00	Buy	Needham

More analyst ratings

$VRCA
Financials

Live finance-specific insights

Verrica Pharmaceuticals Reports Second Quarter 2024 Financial Results
- Reports YCANTH® revenue, net of $4.9M for second quarter of 2024 along with the expansion of YCANTH's distribution footprint to include Cencora, Inc. as a specialty distributor – - Announces positive preliminary topline results of Phase 2 clinical study of VP-315 for the treatment of patients with basal cell carcinoma – - Continues to progress preparation for global Phase 3 Common Warts trial with initiation expected in 1H 2025 – - Conference Call Scheduled for Today at 8:30 am ET – WEST CHESTER, Pa., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica") (NASDAQ:VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical i
8/14/24 7:45:00 AM ET
$VRCA
Biotechnology: Pharmaceutical Preparations
Health Care
Verrica Pharmaceuticals to Report Second Quarter Financial Results and Release Preliminary Topline Results from Part 2 of Phase 2 Trial of VP-315 for the Treatment of Basal Cell Carcinoma on August 14, 2024
WEST CHESTER, Pa., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica" or "the Company") (NASDAQ:VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, August 14, 2024, to discuss the Company's financial results for the second quarter ended June 30, 2024, and provide an overview of topline results from Part 2 of the Phase 2 trial of VP-315 for the treatment of basal cell carcinoma. Individuals may participate in the live call via telephone by dialing 1-800-579-2543 (domestic) or 1-785-424-1789 (international)
8/6/24 7:30:00 AM ET
$VRCA
Biotechnology: Pharmaceutical Preparations
Health Care
Verrica Pharmaceuticals Reports First Quarter 2024 Financial Results
– Reports YCANTH® revenue of $3.2M for first quarter of 2024 – – Over 228 million lives now covered to date on commercial insurance, managed Medicaid, Tricare and Federal Employee plans – – Preliminary Phase 2 results for VP-315 in the treatment of basal cell carcinoma (BCC) expected in the second quarter of 2024 – – Conference Call Scheduled for Today at 8:30 am ET – WEST CHESTER, Pa., May 13, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica") (NASDAQ:VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced financial results for the first quarter ended March 31, 2024. "The first quarter of 2024
5/13/24 7:30:00 AM ET
$VRCA
Biotechnology: Pharmaceutical Preparations
Health Care

$VRCA
Press Releases

Fastest customizable press release news feed in the world

Verrica Announces Pricing of $42.0 Million Public Offering
WEST CHESTER, Pa., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica" or the "Company") (NASDAQ:VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced the pricing of an underwritten public offering of 44,964,045 shares of its common stock and, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase 2,235,955 shares of its common stock, and in either case, accompanying Series A warrants to purchase 23,600,000 shares of its common stock at an exercise price of $1.0680 per share of common stock and Series B warrants to purchase 23,600,000 shares of its commo
11/21/24 7:30:00 AM ET
$VRCA
Biotechnology: Pharmaceutical Preparations
Health Care
Verrica Announces Proposed Public Offering
WEST CHESTER, Pa., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica" or the "Company") (NASDAQ:VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that it intends to offer and sell shares of its common stock (or pre-funded warrants to purchase its common stock in lieu thereof) and in either case, accompanying warrants to purchase shares of its common stock, in an underwritten public offering. All of the securities in the proposed offering will be sold by Verrica. Verrica intends to grant the underwriter a 30-day option to purchase additional shares of its common stock and/or accompanying
11/20/24 4:05:00 PM ET
$VRCA
Biotechnology: Pharmaceutical Preparations
Health Care
Verrica Pharmaceuticals Reports Third Quarter 2024 Financial Results and Announces Leadership Transition
– Company reported $0 in product shipments in the third quarter of 2024 and recognized negative net product revenue of $1.9 million, including a provision for product returns of $1.7 million– – Company expects existing distributor inventory to support most demand for dispensed applicator units into the first quarter of 2025 – – Company continues to look for ways to manage expenses and expand access to YCANTH® for the treatment of molluscum contagiosum – – Company announces new senior leadership with appointments of Dr. Jayson Rieger as Chief Executive Officer and John Kirby as Interim Chi
11/4/24 4:05:00 PM ET
$VRCA
Biotechnology: Pharmaceutical Preparations
Health Care

Verrica Pharmaceuticals Reports Third Quarter 2024 Financial Results and Announces Leadership Transition
– Company reported $0 in product shipments in the third quarter of 2024 and recognized negative net product revenue of $1.9 million, including a provision for product returns of $1.7 million– – Company expects existing distributor inventory to support most demand for dispensed applicator units into the first quarter of 2025 – – Company continues to look for ways to manage expenses and expand access to YCANTH® for the treatment of molluscum contagiosum – – Company announces new senior leadership with appointments of Dr. Jayson Rieger as Chief Executive Officer and John Kirby as Interim Chi
11/4/24 4:05:00 PM ET
$VRCA
Biotechnology: Pharmaceutical Preparations
Health Care
Verrica Pharmaceuticals Reports Second Quarter 2021 Financial Results
WEST CHESTER, Pa., Aug. 10, 2021 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica") (NASDAQ:VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced financial results for the second quarter ended June 30, 2021. "This quarter, we continued to ramp up commercial preparations for the potential FDA approval of VP-102, our lead product candidate for the treatment of molluscum contagiosum, including strengthening our senior leadership team and ensuring patient access to VP-102 through productive dialogue with medical providers and payors," said Ted White, Verrica's President and Chief Executive Officer. "With a
8/10/21 7:30:00 AM ET
$VRCA
Biotechnology: Pharmaceutical Preparations
Health Care
Verrica Pharmaceuticals Announces Appointment of Terry Kohler as Chief Financial Officer
Company strengthens management team in anticipation of the potential commercial launch of VP-102, if approved WEST CHESTER, Pa., July 09, 2021 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica") (NASDAQ:VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced the appointment of Terry Kohler as Chief Financial Officer. Mr. Kohler is a strategic and operational finance leader with over 20 years of commercial business experience, most recently at a global pharmaceutical company with annual revenues over $2 billion. Mr. Kohler is replacing Brian Davis, who is leaving Verrica to pursue other opportunities. "Te
7/9/21 7:30:00 AM ET
$VRCA
Biotechnology: Pharmaceutical Preparations
Health Care

Verrica Pharmaceuticals Settles Litigation, Dormer Labs Halts US Sales of Cantharidin Products

Chat with this insight

Recent Analyst Ratings for $VRCA

$VRCA Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Interim CFO Kirby John J. was granted 54,267 shares (SEC Form 4)

SEC Form 3 filed by new insider Kirby John J.

SEC Form 4 filed by CEO and President Rieger Jayson

$VRCA Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Verrica Pharmaceuticals downgraded by H.C. Wainwright

Verrica Pharmaceuticals downgraded by RBC Capital Mkts

Verrica Pharmaceuticals upgraded by Needham with a new price target

$VRCA Financials

Live finance-specific insights

Verrica Pharmaceuticals Reports Second Quarter 2024 Financial Results

Verrica Pharmaceuticals to Report Second Quarter Financial Results and Release Preliminary Topline Results from Part 2 of Phase 2 Trial of VP-315 for the Treatment of Basal Cell Carcinoma on August 14, 2024

Verrica Pharmaceuticals Reports First Quarter 2024 Financial Results

$VRCA Market Insights

Live Market Insights

$VRCA FDA approvals

Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

$VRCA Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.